Table 1.

Baseline characteristics and pathological results according to biopsy grade group and PSA level.

	Grade group 1			Grade group 2			p*
	PSA < 10 ng/mL (N = 15,301)	PSA 10–20 ng/mL (N = 1731)	p	PSA < 10 ng/mL (N = 8367)	PSA 10–20 ng/mL (N = 1149)	p
Age at diagnosis, year	59.7 ± 7.0	61.8 ± 6.8	<0.001	61.5 ± 6.9	62.9 ± 6.8	<0.001	<0.001
Race/ethnicity			<0.001			0.004	0.067
White	12,649 (82.7%)	1330 (76.8%)		6813 (81.4%)	889 (77.4%)
Black	1769 (11.5%)	259 (15.0%)		1038 (12.4%)	176 (15.3%)
Others/unknown	883 (5.8%)	142 (8.2%)		516 (6.2%)	84 (7.3%)
Clinical T stage			0.247			0.001	<0.001
T1	11,271 (73.7%)	1298 (75.0%)		5872 (70.2%)	860 (74.8%)
T2	4030 (26.3%)	433 (25.0%)		2495 (29.8%)	289 (25.2%)
PSA, ng/mL	5.1 ± 1.9	13.1 ± 2.7	<0.001	5.4 ± 1.9	12.9 ± 2.6	<0.001	<0.001
% Positive cores	17.1 ± 8.0	16.6 ± 8.1	0.026	19.2 ± 7.7	18.9 ± 7.9	0.226	<0.001
Insurance			<0.001			<0.001	0.702
Insured	14,723 (96.2%)	1619 (93.5%)		8072 (96.5%)	1060 (92.3%)
Medicaid	422 (2.8%)	85 (4.9%)		204 (2.4%)	69 (6.0%)
Uninsured	156 (1.0%)	27 (1.6%)		91 (1.1%)	20 (1.7%)
Marital status			<0.001			<0.001	<0.001
Married	12,729 (83.2%)	1341 (77.5%)		6783 (81.1%)	874 (76.1%)
Single	2572 (16.8%)	390 (22.5%)		1584 (18.9%)	275 (23.9%)
Pathologic upgrading at RP			<0.001			<0.001	<0.001
No	14,410 (94.2%)	1530 (88.4%)		7002 (83.7%)	875 (76.2%)
Yes	891 (5.8%)	201 (11.6%)		1365 (16.3%)	274 (23.8%)
Pathologic upstaging at RP			<0.001			<0.001	<0.001
No	14,149 (92.5%)	1478 (85.4%)		6969 (83.3%)	828 (72.1%)
Yes	1152 (7.5%)	253 (14.6%)		1398 (16.7%)	321 (27.9%)
Adverse pathology			<0.001			<0.001	<0.001
No	13,470 (88.0%)	1349 (77.9%)		6027 (72.0%)	672 (58.5%)
Yes	1831 (12.0%)	382 (22.1%)		2340 (28.0%)	477 (41.5%)

PSA prostate-specific antigen, RP radical prostatectomy.

*p value between grade groups.